APA (7th ed.) Citation

Ballantyne, C. M., Neutel, J., Cropp, A., Duggan, W., Wang, E. Q., Plowchalk, D., . . . Bays, H. (2015). Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia. The American journal of cardiology, 115(9), 1212-1221. https://doi.org/10.1016/j.amjcard.2015.02.006

Chicago Style (17th ed.) Citation

Ballantyne, Christie M., et al. "Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia." The American Journal of Cardiology 115, no. 9 (2015): 1212-1221. https://doi.org/10.1016/j.amjcard.2015.02.006.

MLA (9th ed.) Citation

Ballantyne, Christie M., et al. "Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia." The American Journal of Cardiology, vol. 115, no. 9, 2015, pp. 1212-1221, https://doi.org/10.1016/j.amjcard.2015.02.006.